Evidence map›Paper›PMID 41190171›Full record

ArticleBiologics : targets & therapy2025

Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0).

Marisol Bracalenti, Margherita Zen, Benedetta Bianchi, Alessandra Bortoluzzi, Luisa Brussino, Paola Castrignanò, Alberto Cauli, Lorenzo Cavagna, Elisabetta Chessa, Emanuele Chiara and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biologics : targets & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Marisol BracalentiDepartment of Medicine - DIMED, University of Padova, Padova, Italy.
Margherita ZenDepartment of Medicine - DIMED, University of Padova, Padova, Italy.
Benedetta BianchiDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
Alessandra BortoluzziDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Luisa BrussinoDepartment of Medical Sciences, University of Torino, Torino, Italy.ORCID 0000-0001-7249-7616
Paola CastrignanòDepartment of Transplantology, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Alberto CauliDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Lorenzo CavagnaDepartment of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
Elisabetta ChessaDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Emanuele ChiaraDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Rossella De AngelisDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.ORCID 0000-0001-5169-3511
Ginevra De MarchiDepartment of Medicine (DMED), University of Udine, Udine, Italy.
Marco Di CarloDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.ORCID 0000-0002-0906-4647
Giacomo EmmiDepartment of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Isotta GalvagniRheumatology Unit, Department of Medicine, University of Verona, Verona Italy.
Michela GasparottoDepartment of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Mariele GattoDepartment of Medicine - DIMED, University of Padova, Padova, Italy.
Roberto GerliRheumatology Unit, Department of Medicine & Surgery, University of Perugia, Perugia, Italy.
Marcello GovoniDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Alberto Lo GulloUOSD Papardo, Hospital of Messina, Messina, Italy.
Alessia NanoDepartment of Medicine (DMED), University of Udine, Udine, Italy.
Simone NegriniDepartment of Medical Sciences, University of Torino, Torino, Italy.
Silvia NovielloGuido Baccelli Internal Medicine Unit, University of Bari "Aldo Moro", Bari, Italy.
Giovanni OrsoliniRheumatology Unit, Department of Medicine, University of Verona, Verona Italy.
Giulia PazzolaDepartment of Transplantology, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Matteo PigaDepartment of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Luca QuartuccioDepartment of Medicine (DMED), University of Udine, Udine, Italy.
Maurizio RossiniRheumatology Unit, Department of Medicine, University of Verona, Verona Italy.ORCID 0000-0001-9692-2293
Carlo SalvaraniDepartment of Transplantology, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Ettore SilvagniDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Elena SilvestriDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Marianna TamussinDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Martina TizianDepartment of Medicine - DIMED, University of Padova, Padova, Italy.
Paola TomiettoDepartment of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Maria Letizia UrbanDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Angelo VaccaGuido Baccelli Internal Medicine Unit, University of Bari "Aldo Moro", Bari, Italy.ORCID 0000-0002-4567-8216
Andrea DoriaDepartment of Medicine - DIMED, University of Padova, Padova, Italy.
Luca IaccarinoDepartment of Medicine - DIMED, University of Padova, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate the effectiveness of belimumab in different joint and skin phenotypes of systemic lupus erythematosus (SLE). Methods: The BeRLiSS-JS 2.0 is a decade-long observational study including adult SLE patients from 14 Italian Centers treated with belimumab (intravenous/subcutaneous) stratified by articular (nondeforming nonerosive arthritis -NDNE-, Jaccoud's arthropathy, Rhupus) and cutaneous phenotypes (acute -ACLE-, subacute -SCLE-, and chronic cutaneous lupus erythematosus -CCLE-, and nonspecific manifestations). Outcome variables measured every 6 months up to 36 months included Disease Activity Score-28 joints (DAS28) and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores, remission rates (DAS28<2.6; CLASI-A=0), and prednisone intake (mg/day). Results: Of 443 patients, 221 (49.9%) had NDNE, 30 (6.8%) Jaccoud's arthropathy, 21 (4.7%) rhupus, 112 (25.3%) had ACLE, 54 (12.2%) SCLE, and 18 (4.1%) CCLE. At 6 months a significant decrease of DAS28 was observed in NDNE ( Conclusion: Treatment with belimumab was associated with reduced disease activity and increased remission especially in NDNE and ACLE patients. Glucocorticoid-sparing effect was also found.

Indexed as

belimumabjoint manifestationsremissionskin manifestationssystemic lupus erythematosus

Identifiers

PMID41190171
PMCPMC12581791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.